StockNews.com initiated coverage on shares of OncoCyte (NASDAQ:OCX – Free Report) in a report published on Monday morning. The firm issued a sell rating on the stock. OCX has been the topic of a ...

EDT OncoCyte (OCX) files to sell 10.61M shares of common stock for holdersDon't Miss Our End of Quarter Offers: Discover the latest ...

Q4 2024 revenue of $1.5 million in pharma services; full year revenue of $1.9 millionGraftAssure RUO assay launched July ...

Q4 2024 Earnings Call Transcript March 24, 2025 OncoCyte Corporation misses on earnings expectations. Reported EPS is ...

Fintel reports that on March 28, 2025, Lake Street initiated coverage of OncoCyte (NasdaqCM:OCX) with a Buy recommendation.

OncoCyte Corp (OCX) advances with new product launches and strategic alliances, while navigating regulatory hurdles and competitive pressures.

Lake Street Capital initiated coverage on shares of OncoCyte (NASDAQ:OCX – Free Report) in a report released on Friday morning, MarketBeat Ratings reports. The firm issued a buy rating and a $5. ...

Management reiterated its timeline for FDA submission of its clinical assay in late 2025, targeting mid-2026 for market entry. Riggs mentioned cautious optimism about adoption, stating that "the ...

Oncocyte Corp. reports Q4 2024 revenue of $1.5 million, launching a new transplant assay and securing strategic partnerships. Oncocyte Corp. reported a revenue of $1.5 million for Q4 2024 and a ...

Q4 2024 revenue of $1.5 million in pharma services; full year revenue of $1.9 million Our dynamic team is making swift progress toward delivering a regulated organ transplant rejection monitoring ...

As of March 19, 2025, the average one-year price target for OncoCyte is 4.12 GBX/share. The forecasts range from a low of 3.96 GBX to a high of 4.37 GBX. The average price target represents an ...

Q4 2024 revenue of $1.5 million in pharma services; full year revenue of $1.9 million GraftAssure RUO assay launched July 2024 Signed strategic partner and investor, Bio-Rad Laboratories Fully ...